<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34075102</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>p62 overexpression induces TDP-43 cytoplasmic mislocalisation, aggregation and cleavage and neuronal death.</ArticleTitle><Pagination><StartPage>11474</StartPage><MedlinePgn>11474</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11474</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-90822-2</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) that exist on a spectrum of neurodegenerative disease. A hallmark of pathology is cytoplasmic TDP-43 aggregates within neurons, observed in 97% of ALS cases and&#x2009;~&#x2009;50% of FTLD cases. This mislocalisation from the nucleus into the cytoplasm and TDP-43 cleavage are associated with pathology, however, the drivers of these changes are unknown. p62 is invariably also present within these aggregates. We show that p62 overexpression causes TDP-43 mislocalisation into cytoplasmic aggregates, and aberrant TDP-43 cleavage that was dependent on both the PB1 and ubiquitin-associated (UBA) domains of p62. We further show that p62 overexpression induces neuron death. We found that stressors (proteasome inhibition and arsenic) increased p62 expression and that this shifted the nuclear:cytoplasmic TDP-43 ratio. Overall, our study suggests that environmental factors that increase p62 may thereby contribute to TDP-43 pathology in ALS and FTLD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Foster</LastName><ForeName>A D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harry Perkins Institute of Medical Research, University of Western Australia, Crawley, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Flynn</LastName><ForeName>L L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, WA, 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Health Research Building, Discovery Way, Murdoch, WA, 6150, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cluning</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davidson</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polain</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, WA, 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Health Research Building, Discovery Way, Murdoch, WA, 6150, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mejzini</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, WA, 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Health Research Building, Discovery Way, Murdoch, WA, 6150, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrawell</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Wollongong, Wollongong, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yerbury</LastName><ForeName>J J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Wollongong, Wollongong, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Layfield</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Life Sciences, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akkari</LastName><ForeName>P A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, WA, 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Health Research Building, Discovery Way, Murdoch, WA, 6150, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rea</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Harry Perkins Institute of Medical Research, University of Western Australia, Crawley, WA, Australia. sarah.rea@murdoch.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, WA, 6009, Australia. sarah.rea@murdoch.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Health Research Building, Discovery Way, Murdoch, WA, 6150, Australia. sarah.rea@murdoch.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LAYFIELD/APR16/845-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071456">Sequestosome-1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101343">Sqstm1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="Y">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="Y">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071456" MajorTopicYN="N">Sequestosome-1 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34075102</ArticleId><ArticleId IdType="pmc">PMC8169680</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-90822-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-90822-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Couratier P, Corcia P, Lautrette G, Nicol M, Marin B. ALS and frontotemporal dementia belong to a common disease spectrum. Rev. Neurol. (Paris) 2017;173(5):273&#x2013;279. doi: 10.1016/j.neurol.2017.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2017.04.001</ArticleId><ArticleId IdType="pubmed">28449882</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2017;710:132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh N, Pandey UB. Autophagy dysregulation in ALS: When protein aggregates get out of hand. Front. Mol. Neurosci. 2017;10:263. doi: 10.3389/fnmol.2017.00263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00263</ArticleId><ArticleId IdType="pmc">PMC5572252</ArticleId><ArticleId IdType="pubmed">28878620</ArticleId></ArticleIdList></Reference><Reference><Citation>Purice MD, Taylor JP. Linking hnRNP function to ALS and FTD pathology. Front. Neurosci. 2018;12:326. doi: 10.3389/fnins.2018.00326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00326</ArticleId><ArticleId IdType="pmc">PMC5962818</ArticleId><ArticleId IdType="pubmed">29867335</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji AL, Zhang X, Chen WW, Huang WJ. Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum. J. Med. Genet. 2017;54(3):145&#x2013;154. doi: 10.1136/jmedgenet-2016-104271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2016-104271</ArticleId><ArticleId IdType="pubmed">28087719</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008;4(9):e1000193. doi: 10.1371/journal.pgen.1000193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000193</ArticleId><ArticleId IdType="pmc">PMC2527686</ArticleId><ArticleId IdType="pubmed">18802454</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008;64(1):60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Zhang K, Zhai W, Li H, Shen H, Yu Z, et al. TAR DNA binding protein-43 loss of function induced by phosphorylation at S409/410 blocks autophagic flux and participates in secondary brain injury after intracerebral hemorrhage. Front. Cell Neurosci. 2018;12:79. doi: 10.3389/fncel.2018.00079.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00079</ArticleId><ArticleId IdType="pmc">PMC5874314</ArticleId><ArticleId IdType="pubmed">29623031</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q, Wang H, Hao Z, Fu C, Hu Q, Gao F, et al. TDP-43 loss of function increases TFEB activity and blocks autophagosome-lysosome fusion. Embo J. 2016;35(2):121&#x2013;142. doi: 10.15252/embj.201591998.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201591998</ArticleId><ArticleId IdType="pmc">PMC4718457</ArticleId><ArticleId IdType="pubmed">26702100</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Tan W, Whittle C, Qiu L, Cao L, Akbarian S, et al. The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism. PLoS ONE. 2010;5(12):e15878. doi: 10.1371/journal.pone.0015878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0015878</ArticleId><ArticleId IdType="pmc">PMC3013128</ArticleId><ArticleId IdType="pubmed">21209826</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Russ J, Cali CP, Phan JM, Amlie-Wolf A, Lee EB. Loss of nuclear TDP-43 is associated with decondensation of LINE retrotransposons. Cell Rep. 2019;27(5):1409&#x2013;21.e6. doi: 10.1016/j.celrep.2019.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.04.003</ArticleId><ArticleId IdType="pmc">PMC6508629</ArticleId><ArticleId IdType="pubmed">31042469</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J, Guerrero EN, Hegde PM, Liachko NF, Wang H, Vasquez V, et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc. Natl. Acad. Sci. U. S. A. 2019;116(10):4696&#x2013;4705. doi: 10.1073/pnas.1818415116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1818415116</ArticleId><ArticleId IdType="pmc">PMC6410842</ArticleId><ArticleId IdType="pubmed">30770445</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Nonoka T, Kametani F, Yamashita M, Hosokawa M, et al. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology. 2010;30(2):170&#x2013;181. doi: 10.1111/j.1440-1789.2009.01089.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2009.01089.x</ArticleId><ArticleId IdType="pubmed">20102522</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Nonaka T, Hasegawa M, Akiyama H, Yoshida M, Hashizume Y, et al. Neuronal and glial inclusions in frontotemporal dementia with or without motor neuron disease are immunopositive for p62. Neurosci. Lett. 2003;342(1&#x2013;2):41&#x2013;44. doi: 10.1016/S0304-3940(03)00216-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(03)00216-7</ArticleId><ArticleId IdType="pubmed">12727313</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno Y, Amari M, Takatama M, Aizawa H, Mihara B, Okamoto K. Immunoreactivities of p62, an ubiqutin-binding protein, in the spinal anterior horn cells of patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 2006;249(1):13&#x2013;18. doi: 10.1016/j.jns.2006.05.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2006.05.060</ArticleId><ArticleId IdType="pubmed">16820172</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano T, Nakaso K, Nakashima K, Ohama E. Expression of ubiquitin-binding protein p62 in ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis with dementia: Analysis of five autopsy cases with broad clinicopathological spectrum. Acta Neuropathol. 2004;107(4):359&#x2013;364. doi: 10.1007/s00401-004-0821-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-004-0821-7</ArticleId><ArticleId IdType="pubmed">14762676</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanji K, Zhang HX, Mori F, Kakita A, Takahashi H, Wakabayashi K. p62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions. J. Neurosci. Res. 2012;90(10):2034&#x2013;2042. doi: 10.1002/jnr.23081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23081</ArticleId><ArticleId IdType="pubmed">22674379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rea SL, Majcher V, Searle MS, Layfield R. SQSTM1 mutations&#x2013;bridging Paget disease of bone and ALS/FTLD. Exp. Cell Res. 2014;325(1):27&#x2013;37. doi: 10.1016/j.yexcr.2014.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2014.01.020</ArticleId><ArticleId IdType="pubmed">24486447</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J, Strom AL, Kilty R, Zhang F, Zhu H. p62 accumulates and enhances aggregate formation in model systems of familial amyotrophic lateral sclerosis. J. Biol. Chem. 2007;282(15):11068&#x2013;11077. doi: 10.1074/jbc.M608787200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M608787200</ArticleId><ArticleId IdType="pubmed">17296612</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuusisto E, Salminen A, Alafuzoff I. Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: Possible role in tangle formation. Neuropathol. Appl. Neurobiol. 2002;28(3):228&#x2013;237. doi: 10.1046/j.1365-2990.2002.00394.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2990.2002.00394.x</ArticleId><ArticleId IdType="pubmed">12060347</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooten MW, Seibenhener ML, Mamidipudi V, Diaz-Meco MT, Barker PA, Moscat J. The atypical protein kinase C-interacting protein p62 is a scaffold for NF-kappaB activation by nerve growth factor. J. Biol. Chem. 2001;276(11):7709&#x2013;7712. doi: 10.1074/jbc.C000869200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C000869200</ArticleId><ArticleId IdType="pubmed">11244088</ArticleId></ArticleIdList></Reference><Reference><Citation>Haack TB, Ignatius E, Calvo-Garrido J, Iuso A, Isohanni P, Maffezzini C, et al. Absence of the autophagy adaptor SQSTM1/p62 causes childhood-onset neurodegeneration with ataxia, dystonia, and gaze palsy. Am. J. Hum. Genet. 2016;99(3):735&#x2013;743. doi: 10.1016/j.ajhg.2016.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.06.026</ArticleId><ArticleId IdType="pmc">PMC5010644</ArticleId><ArticleId IdType="pubmed">27545679</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh Babu J, Lamar Seibenhener M, Peng J, Strom AL, Kemppainen R, Cox N, et al. Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. J. Neurochem. 2008;106(1):107&#x2013;120. doi: 10.1111/j.1471-4159.2008.05340.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2008.05340.x</ArticleId><ArticleId IdType="pubmed">18346206</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsui S, Otomo A, Nozaki M, Ono S, Sato K, Shirakawa R, et al. Systemic overexpression of SQSTM1/p62 accelerates disease onset in a SOD1(H46R)-expressing ALS mouse model. Mol. Brain. 2018;11(1):30. doi: 10.1186/s13041-018-0373-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-018-0373-8</ArticleId><ArticleId IdType="pmc">PMC5975400</ArticleId><ArticleId IdType="pubmed">29843805</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T, Adachi Y, Yanagawa T, Iijima M, Sesaki H. p62/sequestosome-1 knockout delays neurodegeneration induced by Drp1 loss. Neurochem. Int. 2018;117:77&#x2013;81. doi: 10.1016/j.neuint.2017.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2017.05.012</ArticleId><ArticleId IdType="pmc">PMC5847479</ArticleId><ArticleId IdType="pubmed">28527629</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavey JR, Ralston SH, Hocking LJ, Sheppard PW, Ciani B, Searle MS, et al. Loss of ubiquitin-binding associated with Paget's disease of bone p62 (SQSTM1) mutations. J. Bone Miner. Res. 2005;20(4):619&#x2013;624. doi: 10.1359/JBMR.041205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1359/JBMR.041205</ArticleId><ArticleId IdType="pubmed">15765181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Roos PM, Piehl F, Kamel F, Fang F. Risk factors for amyotrophic lateral sclerosis. Clin. Epidemiol. 2015;7:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkonde YV, Jawaid A, Qureshi SU, Shirani P, Wheaton M, Pinto-Patarroyo GP, et al. Medical and environmental risk factors associated with frontotemporal dementia: A case-control study in a veteran population. Alzheimers Dement. 2012;8(3):204&#x2013;210. doi: 10.1016/j.jalz.2011.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.011</ArticleId><ArticleId IdType="pubmed">22465176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HK, Lee YC, Huang CY, Liliang PC, Lu K, Chen HJ, et al. Traumatic brain injury causes frontotemporal dementia and TDP-43 proteolysis. Neuroscience. 2015;300:94&#x2013;103. doi: 10.1016/j.neuroscience.2015.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.05.013</ArticleId><ArticleId IdType="pubmed">25982564</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson EN, Gochenaur L, Singh A, Grant R, Patel K, Watkins S, et al. Traumatic injury induces stress granule formation and enhances motor dysfunctions in ALS/FTD models. Hum. Mol. Genet. 2018;27(8):1366&#x2013;1381. doi: 10.1093/hmg/ddy047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy047</ArticleId><ArticleId IdType="pmc">PMC6455923</ArticleId><ArticleId IdType="pubmed">29432563</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiesner D, Tar L, Linkus B, Chandrasekar A, Olde Heuvel F, Dupuis L, et al. Reversible induction of TDP-43 granules in cortical neurons after traumatic injury. Exp. Neurol. 2018;299(Pt A):15&#x2013;25. doi: 10.1016/j.expneurol.2017.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2017.09.011</ArticleId><ArticleId IdType="pubmed">28941811</ArticleId></ArticleIdList></Reference><Reference><Citation>Che MX, Jiang YJ, Xie YY, Jiang LL, Hu HY. Aggregation of the 35-kDa fragment of TDP-43 causes formation of cytoplasmic inclusions and alteration of RNA processing. Faseb J. 2011;25(7):2344&#x2013;2353. doi: 10.1096/fj.10-174482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.10-174482</ArticleId><ArticleId IdType="pubmed">21450909</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Meng P, Zheng Y, Mao Y, Hu F. Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. J. Neurochem. 2011;116(2):248&#x2013;259. doi: 10.1111/j.1471-4159.2010.07098.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.07098.x</ArticleId><ArticleId IdType="pubmed">21062285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerbury JJ, Farrawell NE, McAlary L. Proteome homeostasis dysfunction: A unifying principle in ALS pathogenesis. Trends Neurosci. 2020;43(5):274&#x2013;284. doi: 10.1016/j.tins.2020.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.03.002</ArticleId><ArticleId IdType="pubmed">32353332</ArticleId></ArticleIdList></Reference><Reference><Citation>De Conti L, Akinyi MV, Mendoza-Maldonado R, Romano M, Baralle M, Buratti E. TDP-43 affects splicing profiles and isoform production of genes involved in the apoptotic and mitotic cellular pathways. Nucleic Acids Res. 2015;43(18):8990&#x2013;9005. doi: 10.1093/nar/gkv814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv814</ArticleId><ArticleId IdType="pmc">PMC4605304</ArticleId><ArticleId IdType="pubmed">26261209</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiga A, Ishihara T, Miyashita A, Kuwabara M, Kato T, Watanabe N, et al. Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. PLoS ONE. 2012;7(8):e43120. doi: 10.1371/journal.pone.0043120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0043120</ArticleId><ArticleId IdType="pmc">PMC3416794</ArticleId><ArticleId IdType="pubmed">22900096</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, L&#xf3;pez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 2019;22(2):180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Yokoshi M, Okada H, Kawahara Y. The cleavage pattern of TDP-43 determines its rate of clearance and cytotoxicity. Nat. Commun. 2015;6:6183. doi: 10.1038/ncomms7183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7183</ArticleId><ArticleId IdType="pubmed">25630387</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Lin F, Robertson CS, Wang KK. Dual vulnerability of TDP-43 to calpain and caspase-3 proteolysis after neurotoxic conditions and traumatic brain injury. J. Cereb. Blood Flow Metab. 2014;34(9):1444&#x2013;1452. doi: 10.1038/jcbfm.2014.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2014.105</ArticleId><ArticleId IdType="pmc">PMC4158661</ArticleId><ArticleId IdType="pubmed">24917042</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, Bailey R, et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J. Neurosci. 2007;27(39):10530&#x2013;10534. doi: 10.1523/JNEUROSCI.3421-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3421-07.2007</ArticleId><ArticleId IdType="pmc">PMC6673167</ArticleId><ArticleId IdType="pubmed">17898224</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Horton DK, Mitsumoto H. Potential environmental factors in amyotrophic lateral sclerosis. Neurol. Clin. 2015;33(4):877&#x2013;888. doi: 10.1016/j.ncl.2015.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.009</ArticleId><ArticleId IdType="pmc">PMC4646848</ArticleId><ArticleId IdType="pubmed">26515627</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber SC, Shaw PJ. Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target. Free Radic. Biol. Med. 2010;48(5):629&#x2013;641. doi: 10.1016/j.freeradbiomed.2009.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.11.018</ArticleId><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster CP, Smith EF, Shaw PJ, De Vos KJ. Protein homeostasis in amyotrophic lateral sclerosis: Therapeutic opportunities? Front. Mol. Neurosci. 2017;10:123. doi: 10.3389/fnmol.2017.00123.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00123</ArticleId><ArticleId IdType="pmc">PMC5411428</ArticleId><ArticleId IdType="pubmed">28512398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichimura Y, Kumanomidou T, Sou YS, Mizushima T, Ezaki J, Ueno T, et al. Structural basis for sorting mechanism of p62 in selective autophagy. J. Biol. Chem. 2008;283(33):22847&#x2013;22857. doi: 10.1074/jbc.M802182200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M802182200</ArticleId><ArticleId IdType="pubmed">18524774</ArticleId></ArticleIdList></Reference><Reference><Citation>Rea SL, Walsh JP, Ward L, Yip K, Ward BK, Kent GN, et al. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype. J. Bone Miner. Res. 2006;21(7):1136&#x2013;1145. doi: 10.1359/jbmr.060405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1359/jbmr.060405</ArticleId><ArticleId IdType="pubmed">16813535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 2005;171(4):603&#x2013;614. doi: 10.1083/jcb.200507002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200507002</ArticleId><ArticleId IdType="pmc">PMC2171557</ArticleId><ArticleId IdType="pubmed">16286508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A, Kolarich D, Haynes PA, Jensen PH, Baker MS, Packer NH. Rat liver membrane glycoproteome: Enrichment by phase partitioning and glycoprotein capture. J. Proteome Res. 2009;8(2):770&#x2013;781. doi: 10.1021/pr800910w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr800910w</ArticleId><ArticleId IdType="pubmed">19125615</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>